The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.

Cardiovascular Therapeutics
Pieter MartensWilfried Mullens

Abstract

Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied. We performed a single-center, prospective assessor-blinded study to determine the reverse remodeling response of sacubitril/valsartan therapy in HFrEF patients with a class I indication (New York heart Association [NYHA]-class II-IV, Left ventricular ejection fraction [LVEF] < 35%, optimal dose with Renin-Angiotensin-System-Blocker [RAS-blocker]). Doses of sacubitril/valsartan were optimized to individual tolerance. Echocardiographic images were assessed offline by 2 investigators blinded to both the clinical data and timing of echocardiograms. One-hundred-twenty-five HFrEF patients (66 ± 10 years) were prospectively included. The amount of RAS-blocker before and after switch to sacubitril/valsartan was similar(P = .290), indicating individual optimal dosing of sacubitril/valsartan. Over a median(IQR) follow-up of 118(77-160) days after initiation of sacubitril/valsartan, LVEF improved (29.6 ± 6% vs 34.8 ± 6%; P < .001) and Left ventricular end-systolic (LVESV) and end-diastolic volume (LVEDV) decreased (LVESV; 147 ± 57 mL vs 129 ± 55 mL; P...Continue Reading

References

Jul 15, 1992·The American Journal of Cardiology·C O GøtzscheK Thygesen
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Dec 29, 2000·Journal of the American College of Cardiology·B A GroenningP R Hildebrandt
Jul 11, 2002·Journal of the American College of Cardiology·Mariantonietta CicoiraPiero Zardini
Sep 13, 2002·Journal of the American College of Cardiology·Maylene WongUNKNOWN Val-HeFT Heart Failure Trial Investigators
Aug 19, 2007·Journal of the American College of Cardiology·Anna K Y ChanCheuk-Man Yu
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Mar 16, 2016·Circulation·Scott A Hubers, Nancy J Brown
Apr 3, 2016·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Sherif F NaguehAlan D Waggoner
Aug 30, 2016·Annals of Internal Medicine·Milton PackerMichael Emmett
Mar 13, 2017·Journal of Cardiac Failure·Pieter MartensWilfried Mullens
May 30, 2017·Progress in Cardiovascular Diseases·Petra NijstWilfried Mullens
Jun 27, 2017·NPJ Systems Biology and Applications·Oriol Iborra-EgeaAntoni Bayes-Genis

❮ Previous
Next ❯

Citations

Feb 12, 2019·European Journal of Heart Failure·Jozine M Ter Maaten
Mar 12, 2019·Circulation·Wilfried Mullens, Pieter Martens
Dec 28, 2018·Circulation·Duk-Hyun KangJae-Joong Kim
Mar 22, 2019·Current Medical Research and Opinion·Luca MonzoLeonardo Calò
Jun 27, 2019·Journal of the American Heart Association·Yiwen WangDongye Li
Jul 11, 2019·Journal of Comparative Effectiveness Research·Herminio Morillas-ClimentAlfonso Valle-Muñoz
Feb 23, 2019·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Pieter MartensWilfried Mullens
Jun 11, 2019·Cardiac Failure Review·Lampros PapadimitriouRobert C Long
Jan 29, 2020·Journal of Cardiovascular Medicine·António Valentim GonçalvesRui C Ferreira
Apr 23, 2020·Future Cardiology·Pramod Kumar Kuchulakanti
Nov 8, 2019·Acta Cardiologica·Pieter MartensWilfried Mullens
Jun 20, 2020·Heart Failure Reviews·Andrea Lorenzo VecchiMichele Senni
Mar 2, 2019·Cardiovascular Drugs and Therapy·Carles Moliner-AbósEulàlia Roig
Dec 31, 2019·ESC Heart Failure·Markus S AnkerUNKNOWN Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology
Sep 14, 2019·Journal of Cardiovascular Pharmacology and Therapeutics·Fu-Chih HsiaoPao-Hsien Chu
Aug 4, 2020·Journal of Cardiovascular Medicine·Alessandra VillaniGabriella Malfatto
Jul 4, 2020·BMC Cardiovascular Disorders·Damien LegalloisFarzin Beygui
Oct 9, 2020·Journal of Cardiovascular Pharmacology·Jingwen HuQijun Shan
Jan 24, 2021·Clinical Drug Investigation·Matteo CasaleGiuseppe Dattilo
Jan 23, 2021·Current Heart Failure Reports·Andrew Abboud, James L Januzzi
Nov 3, 2020·Cardiac Failure Review·Davide MargonatoAndrea Mortara
Feb 19, 2021·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Pere PericasXavier Rossello
Mar 9, 2021·Frontiers in Physiology·Carles Moliner-AbósJesús Álvarez-García
Apr 23, 2021·Journal of Pharmacy Practice·Nicholas J OrvinStuart D Russell
Apr 28, 2021·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Agata BuonaceraLorenzo Malatino
May 27, 2021·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Wilfried MullensChristophe Leclercq
Jun 12, 2021·Medicinal Research Reviews·Hanne BeliënAnnelies Bronckaers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.